New platic complexes for anticancer therapy (Q10095): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Changed label, description and/or aliases in 2 languages: Changing unique label-description pair)
(‎Removed claim: financed by (P890): Directorate-General for Regional and Urban Policy (Q8361), Removing unnecessary financed by statement)
Property / financed by
 
Property / financed by: Directorate-General for Regional and Urban Policy / rank
Normal rank
 

Revision as of 15:31, 28 October 2020

Project Q10095 in Czech Republic
Language Label Description Also known as
English
New platic complexes for anticancer therapy
Project Q10095 in Czech Republic

    Statements

    0 references
    5,848,500.0 Czech koruna
    0 references
    233,940.0 Euro
    10 January 2020
    0 references
    15,596,000.0 Czech koruna
    0 references
    623,840.0 Euro
    10 January 2020
    0 references
    37.5 percent
    0 references
    15 June 2016
    0 references
    28 September 2019
    0 references
    VUAB Pharma a.s.
    0 references
    0 references

    50°9'46.91"N, 14°23'2.26"E
    0 references
    25263
    0 references
    Předmětem řešení projektu jsou nové platičité komplexy (Pt(IV)komplexy) se zvýšenou reaktivitou ve vnitrobuněčném prostředí vyznačené tím, že obsahují slabě vázané a potenciálně reaktivní ekvatoriální anion-ligandy bází silných konjugovaných kyselin. Výsledkem řešení bude zcela nová skupina Pt(IV)komplexů pro protinádorovou terapii se zvýšenou toxicitou a selektivitou na nádorové buňky, s malou toxicitou na zdravé buňky a s dobrou biologickou dostupností z GIT, umožňující perorální podání. a. (Czech)
    0 references
    The object of the project is new platic complexes (Pt(IV)complexes) with increased reactivity in the intracellular environment marked by the fact that they contain weakly bound and potentially reactive equatorial anion-ligands bases of strong conjugated acids. The result of the solution will be a completely new group of Pt(IV)complexes for anticancer therapy with increased toxicity and selectivity to tumor cells, with low toxicity to healthy cells and with good bioavailability from GIT, allowing oral administration. a. (English)
    22 October 2020
    0 references

    Identifiers

    CZ.01.1.02/0.0/0.0/15_018/0004605
    0 references